期刊文献+

替格瑞洛原料药中有关物质的HPLC法测定

Determination of the Related Substances in Bulk Drug of Ticagrelor by HPLC
原文传递
导出
摘要 建立了高效液相色谱法测定替格瑞洛原料药中的有关物质。使用Agilent Zorbax SB-C18色谱柱,以1.0 mol/L磷酸二氢钠缓冲液(pH 3.0)∶乙腈(90∶10)为流动相A,1.0 mol/L磷酸二氢钠缓冲液(p H 3.0)∶乙腈(30∶70)为流动相B,梯度洗脱,检测波长242 nm。替格瑞洛及其各有关物质(A^K)分离完全。有关物质A、D、E、F、G、H、I、J和K在各自定量限浓度至1.5mg/ml范围内线性关系良好,有关物质B和C在各自定量限浓度至3.0mg/ml范围内线性关系良好;平均回收率为95.1%~108.0%,RSD为0.83%~4.54%。 An HPLC method was established for the determination of the related substances in bulk drug of ticagrelor. An Agilent Zorbax SB-C18 column was used, with the mobile phase A of sodium dihydrogen phosphate buffer (1.0 mol/L) : acetonitrile (90 : 10), and mobile phase B of sodium dihydrogen phosphate buffer (1.0 mol/L) : acetonitrile (30 :70), by gradient elution at the detection wavelength of 242 nm. The peaks of the related substances and ticagrelor could be separated well. The method was found to be linear in the ranges of their LOQs to 1.5 lag/ml for the related substances A, D, E, F, G, H, I, J and K, in the ranges of their LOQs to 3.0 μg/ml for related substances B and C. Their average recoveries were 95.1% - 108.0 %, with RSDs of 0.83 % -4.54 %.
出处 《中国医药工业杂志》 CAS CSCD 北大核心 2016年第11期1445-1449,共5页 Chinese Journal of Pharmaceuticals
关键词 替格瑞洛 有关物质 高效液相色谱 含量测定 ticagrelor related substance HPLC content determination
  • 相关文献

参考文献3

  • 1姚懿,袁晋青.新型抗血小板药物普拉格雷、替格瑞洛与氯吡格雷的临床对比研究进展[J].中华临床医师杂志,2013,7(19):8870-8873.
  • 2邱怡敏,夏海燕.抗血小板新药替格瑞洛的应用现状及前景[J].世界临床药物,2015,36(11):784-788. 被引量:4
  • 3孙绍光,宋德福,何彪,等.替格瑞洛的中间体及其制备方法和替格瑞洛的制备方法:中国,104098553A[P].2014-10-15.

二级参考文献15

  • 1Teng R,Butler K. Pharmacokinetics, pharmacodynamics,safety and tolerability of multiple ascending doses of ticagrelorin healthy volunteers [J]. Br J Clin Pharmacol, 2010,70(1):65-77.
  • 2Wijeyeratne YD, Joshi R, Heptinstall S. Ticagrelor-a P2Y12antagonist for use in acute coronary syndromes [J]. Expert RevClin Pharmacol, 2012, 5 ⑶:257-269.
  • 3Butler K, Teng R. Pharmacokinetics, pharmacodynamics,and safety ofticagrelor in volunteers with severe renalimpairment [J]. J Clin Pharmacol, 2012, 52(9): 1388-1398.
  • 4Butler K, Teng R. Pharmacokinetics, pharmacodynamics,and safety of ticagrelor in volunteers with mild hepaticimpairment [J]. J Clin Pharmacol, 2011,51 (7): 978-987.
  • 5Gurbel PA, Bliden KP,Butler K, et al. Randomizeddoubleblind assessment of the ONSET and OFFSET of theantiplatelet effects of ticagrelor versus clopidogrel in patientswith stable coronary artery disease:the ONSET/OFFSETstudy [J]. Circulation, 2009, 120(25): 2577-2585.
  • 6Gurbel PA, Bliden KP, Butler K, et al. Response to ticagrelorin clopidogrel nonresponders and responders and effect ofswitching therapies: the RESPOND study [J]. Circulation,2010, 121(10): 1188-1199.
  • 7Bonaca MP,Bhatt DL, Cohen M, et al. Long-term use ofticagrelor in patients with prior myocardial infarction [J]. NEngl J Med, 2015,372 (19): 1791-1800.
  • 8James S,A kerblom A, Cannon C, et al. Comparison ofticagrelor, the first reversible oral P2Y (12) receptor antagonist,with clopidogrel in patients with acute coronary syndromes:Rationale, design, and baseline characteristics of the PLATeletinhibition and patient Outcomes (PLATO) trial [J]. Am Heart J,2009, 157(4): 599-605.
  • 9James SK, Roe MT, Cannon CP, et al. Ticagrelor versusclopidogrel in patients with acute coronary syndromesintended for non-invasive management: substudy fromprospective randomised PLATelet inhibition and patientOutcomes (PLATO) trial [J]. Br Med J, 2011, 342: d3527.
  • 10Costa F, Ariotti S, Valgimigli M, et al. Perspectives on the2014 ESC/EACTS Guidelines on myocardial revascularization:fifty years of revascularization: where are we and where are weheading. [J]. J Cardiovasc Transl Res, 2015, 8 (4): 211-220.

共引文献6

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部